Cisatracurium Besilate (NIMBEX cisatracurium (as besilate) 5mg/2.5mL injection ampoule)
What to know about Cisatracurium Besilate — also sold as NIMBEX cisatracurium (as besilate) 5mg/2.5mL injection ampoule, NIMBEX cisatracurium (as besilate) 10mg/5mL injection ampoule, NIMBEX cisatracurium (as besilate) 20mg/10mL injection ampoule: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
Cisatracurium Besilate (brand names: NIMBEX cisatracurium (as besilate) 5mg/2.5mL injection ampoule, NIMBEX cisatracurium (as besilate) 10mg/5mL injection ampoule, NIMBEX cisatracurium (as besilate) 20mg/10mL injection ampoule) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. FDA approved in the United States. Neuromuscular blocking agent used in anaesthesia with significant respiratory depression risk.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (3 points)
- CNS depressant: May cause sedation, impair driving, and affect work capacity
- Respiratory depression risk: Requires monitoring, especially with other CNS depressants
- Recommended maximum duration: 1 days
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
| United States (FDA) | Rx only | FDA approved |
Risk Profile
Neuromuscular blocking agent used in anaesthesia with significant respiratory depression risk.
How Cisatracurium Besilate is regulated
Cisatracurium Besilate is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Work capacity impact: As a CNS depressant, Cisatracurium Besilate may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
United Kingdom NICE / MHRA / FPM
UK drug driving laws (Section 5A Road Traffic Act 2006) set specific limits for prescription drugs that cause impairment. Employers and occupational health advisors should assess fitness to work.
United States FDA / CDC / State WC
FDA approved for use in the United States.
Check this medication against your full medication list
Run a full risk assessment including Cisatracurium Besilate interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.